Business Context and Reporting Period
Company: Cognition Therapeutics, Inc. (CGTX)
Filing Type: Form 8-K (Current Report)
Report Date: March 26, 2026
Reporting Period: The filing announces financial results for the fiscal year ended December 31, 2025. The company is classified as an emerging growth company.
Key Financial Metrics
The provided text is a cover sheet and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not include specific numerical values within this document.
- Revenue, Profit, Cash Flow, Margins: Not provided in the filing text; contained in referenced Exhibit 99.1.
- Debt and Liquidity: Not provided in the filing text; contained in referenced Exhibit 99.1.
Material Changes
The filing text does not contain specific data to compare against prior periods. It serves solely to notify the market of the issuance of the press release regarding the 2025 full-year results.
Guidance, Outlook, and Risks
Management Commentary: The filing includes an investor presentation (Exhibit 99.2) furnished under Regulation FD, which may contain outlook or strategic commentary, but the text of the presentation is not included in this document.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text. The filing includes standard disclaimers that the furnished information is not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the year ended December 31, 2025.
- Examine Exhibit 99.2 (Investor Presentation) for management's forward-looking statements and strategic updates.
- Verify the company's status as an emerging growth company and any associated accounting election impacts.
- Confirm the trading symbol CGTX on The Nasdaq Stock Market LLC.